Compare PEO & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PEO | LBRX |
|---|---|---|
| Founded | 1929 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.8M | 602.6M |
| IPO Year | N/A | N/A |
| Metric | PEO | LBRX |
|---|---|---|
| Price | $26.74 | $25.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $50.67 |
| AVG Volume (30 Days) | 109.9K | ★ 230.9K |
| Earning Date | 01-01-0001 | 05-09-2026 |
| Dividend Yield | ★ 5.93% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.30 | $13.40 |
| 52 Week High | $28.88 | $27.55 |
| Indicator | PEO | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.65 | 55.69 |
| Support Level | $21.14 | $22.39 |
| Resistance Level | $27.12 | $27.55 |
| Average True Range (ATR) | 0.73 | 1.48 |
| MACD | -0.17 | 0.15 |
| Stochastic Oscillator | 37.87 | 65.43 |
Adams Natural Resources Fund Inc is a non-diversified U.S. equity fund that invests in liquid energy and other natural resources stocks. The Fund's investment objectives are preservation of capital, reasonable income, and opportunity for capital gain. A majority of its assets are invested in petroleum or natural resources industries or industries connected to them. It has broad flexibility to invest in stocks of varying capitalizations and predominantly invests in stocks found in the S&P 500 Energy and S&P 500 Materials sectors.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.